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CASE
A 59-year-old male with a past medical history of rheumatoid arthritis for which hewas on high-dose prednisone (20 mg daily) for more than 3 years, chronic
obstructive pulmonary disease, chronic lower back pain, lower extremity neuropathy,
gout, and hypertension presented to the emergency department (ED) with a 2-day
history of increasing shortness of breath and subjective fever. The patient had a family
history signiﬁcant for heart disease but denied any personal history of coronary artery
or valvular heart disease. The patient also noted an ulceration on his right great toe
with drainage for 1 to 2 months. Upon arrival in the ED, the patient was tachycardic
(heart rate, 100 to 149 bpm) and febrile to 39.4°C with normal respiration (blood
oxygen saturation [SpO2], 94%). Initial laboratory studies were signiﬁcant for elevated
white blood cells at 18,600 cells/mm3 (reference, 3,800 to 9,000), 91.4% neutrophils,
lactate at 5.9 mmol/liter (reference, 0.5 to 2.2), and N-terminal pro-b-type natriuretic
peptide (NT-pro-BNP) of 151 (reference, 52 to 125 pg/ml). On physical examination, a
1-cm ulcer was noted on his great right toe that was associated with erythema but from
which no sinus tract or signiﬁcant purulence was noted. Chest, abdomen, and pelvis
computed tomography with contrast revealed minor bronchiolar densities in the right
upper lobe, likely representing early pulmonary bronchiolitis. Two sets of blood cultures
were obtained, and the patient was started on intravenous (i.v.) levoﬂoxacin and i.v.
metronidazole. Twelve hours into incubation, the aerobic and anaerobic bottles (Ver-
saTrek, TREK Diagnostic Systems, Cleveland, OH) of both sets of blood cultures signaled
positive, and short Gram-positive bacilli with rounded ends were observed on Gram
stain (Fig. 1A and B), prompting initiation of empirical treatment with i.v. vancomycin,
cefepime, and metronidazole. Within 1 day, pinpoint, alpha-hemolytic colonies grew on
5% sheep blood and chocolate agars incubated at 37°C in 5% CO2 and brucella blood
agars incubated anaerobically (Fig. 1C). The isolate was identiﬁed as Erysipelothrix
rhusiopathiae with scores of 2.26 and 2.14 using the research use only (RUO) BDAL v7
database of the Bruker biotyper matrix-assisted laser desorption ionization–time of
ﬂight mass spectrometry (MALDI-TOF MS; Billerica, MA), indicating a high-conﬁdence
species-level identiﬁcation (scores, 2.0). Additional biochemical testing demonstrated
that the isolate was catalase negative, resistant to vancomycin (30 g; BD, Sparks, MD),
and produced hydrogen sulﬁde when incubated on triple sugar iron (TSI) Agar (Remel,
Lenexa, KS), consistent with Erysipelothrix rhusiopathiae (Fig. 1D and E).
Following report of the E. rhusiopathiae result, the patient’s antimicrobial therapy
was switched to i.v. penicillin G and a transesophageal echocardiogram (TEE) was
performed. A 0.9- by 0.5-cm vegetation was seen on the posterior mitral leaﬂet
consistent with endocarditis. No signiﬁcant valve destruction was found, precluding
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surgical intervention, but mild mitral regurgitation was noted. The open wound on the
patient’s right great toe was thought to be the source of infection, as the patient
reported frequently walking barefoot at home and has pet cats and dogs. Drainage
ﬂuid from the ulcer was submitted for aerobic culture. Gram stain of the primary
specimen demonstrated no inﬂammatory cells or organisms seen, and the culture grew
rare mixed Gram-positive organisms. X-ray and magnetic resonance imaging of the
right foot revealed soft tissue swelling and no evidence of osteomyelitis. The patient
remained clinically asymptomatic and was discharged with 6 weeks of i.v. penicillin G.
At 4 weeks postdischarge, the patient was readmitted with low-grade fevers and left
upper extremity swelling consistent with deep vein thrombosis secondary to the
peripherally inserted central catheter line. Posttreatment blood cultures remained
negative, and follow-up TEE ﬁndings were unchanged compared with those of previous
studies. The patient completed the remaining week of antimicrobial therapy with i.v.
ceftriaxone and recovered with no further complications.
DISCUSSION
Erysipelothrix rhusiopathiae is a facultative anaerobic non-spore-forming Gram-
positive bacillus. First isolated by Koch in 1880, E. rhusiopathiae was identiﬁed as the
causative agent of swine erysipelas and later recovered from a human patient with
localized infection in 1909 (1). E. rhusiopathiae is widely distributed but is most
frequently associated with pigs and can also be found in the digestive tracts of various
FIG 1 Phenotypic and biochemical features of Erysipelothrix rhusiopathiae. (A) Gram stain of positive
blood culture broth demonstrating Gram-positive bacilli. (B) Inset of image (A) highlighting Gram-
positive bacilli appearing at times Gram negative (arrows). (C) Small, alpha-hemolytic colonies of E.
rhusiopathiae growing on 5% sheep blood agar after 3 days of incubation. (D) Growth of E. rhusiopathiae
isolate abuts 30-g vancomycin disk demonstrating vancomycin resistance. (E) Hydrogen sulﬁde pro-
duction is noted by formation of black precipitate when a triple sugar iron (TSI) Agar slant is inoculated
with E. rhusiopathiae.
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animals, including ﬁsh, sheep, and cattle, as well as dogs and cats. Two additional
species in the genus, namely Erysipelothrix tonsillarum and Erysipelothrix inopinata, have
been recovered from the tonsils of healthy pigs and cattle and the environment.
Although a rare cause of human infection, E. rhusiopathiae enters the environment
when shed in the urine or feces of infected animals and are transmitted to humans from
direct contact through cuts, abrasions, and injuries.
E. rhusiopathiae is largely a zoonotic pathogen that can cause disease in a variety of
animals. In pigs, E. rhusiopathiae can cause an acute infection characterized by septi-
cemia and diffuse erythema resulting in sudden death. Subacute and chronic infections
presenting as cutaneous lesions or local arthritis and endocarditis can also occur. In
other animals, including sheep, cattle, and birds, E. rhusiopathiae can cause skin lesions
and arthritis and can result in death (2).
Human Erysipelothrix sp. infection is rare and is usually due to exposure to infected
animals, such as ﬁsh or swine. As such, individuals with occupational exposures to
animals or animal products, such as veterinarians, abattoir workers, and ﬁsherman, are
at greatest risk for infection (3). Infections can manifest in one of the following three
forms: (i) a localized cutaneous lesion or erysipeloid, (ii) a generalized cutaneous form,
and (iii) a septicemic form which is often associated with infectious endocarditis. In the
localized cutaneous form, the erysipeloid develops 2 to 4 days postexposure, and
infection is typically limited to the ﬁngers or hand. Surface swabs are not useful for
isolation of E. rhusiopathiae from cutaneous lesions since the organisms reside deep in
the subdermal layer. Rather, biopsy specimens are optimal for isolation of the organism.
In bloodstream infections, E. rhusiopathiae can be recovered from standard blood
cultures and is strongly associated with endocarditis. E. rhusiopathiae endocarditis
occurs in patients with underlying heart conditions and animal exposure and can have
mortality approaching 40% (1). Although as many as 90% of E. rhusiopathiae blood-
stream infections are associated with endocarditis, newer reports suggest endocarditis
due to systemic E. rhusiopathiae infection is rare (4). In the absence of occupational
exposures, risk factors for invasive Erysipelothrix rhusiopathiae infection include immu-
nocompromising conditions, such as chronic kidney disease, diabetes mellitus, and
treatment with high-dose steroids (as was the case with this patient). In patients with
E. rhusiopathiae endocarditis, excessive alcohol use, in addition to underlying heart
conditions, has also been identiﬁed as a signiﬁcant risk factor (1, 4).
Identiﬁcation of Erysipelothrix species can present some diagnostic challenges. The
organism can have an uneven Gram stain appearance and may even appear Gram
negative at times, similar to this case (Fig. 1A and B). Colonies are pinpoint and
alpha-hemolytic on routine medium, as shown in Fig. 1C, and the short Gram-positive
rods can resemble streptococci and enterococci. Similar to enterococci, E. rhusiopathiae
is also positive for pyrrolidonyl aminopeptidase (PYR) activity, which may contribute to
misidentiﬁcation. Erysipelothrix species can be differentiated from enterococci by the
ability to produce hydrogen sulﬁde (H2S) on TSI Agar (Fig. 1E). Biochemical testing and
Gram stain appearance may readily distinguish Erysipelothrix sp. isolates from other
non-spore-forming Gram-positive bacilli, including Corynebacterium spp., Listeria mono-
cytogenes, and Lactobacillus spp. (Table 1). Positive catalase reactions differentiate
Corynebacterium spp. and Listeria spp. from Erysipelothrix spp., which are negative for
most rapid biochemical tests, including catalase, oxidase, indole, methyl red, Voges-
Proskauer, and hydrolysis of esculin or urea (5). Lactobacillus species are catalase-
negative long, slender Gram-positive bacilli that can be vancomycin resistant and are
also associated with bloodstream infection and endocarditis. However, Lactobacillus
species are negative for H2S production on TSI Agar. Another unique characteristic of
E. rhusiopathiae is the “bottle-brush” or “pipe cleaner” appearance of growth in a
gelatin stab. Further biochemical testing is necessary for species-level differentiation of
E. rhusiopathiae from E. tonsillarum, which ferments sucrose and is positive for alkaline
phosphatase (5).
Automated identiﬁcation systems, including Vitek2 (bioMérieux, Durham, NC) and
BD Phoenix (BD Diagnostics, Sparks, MD), as well as the API Coryne and Strep systems
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(bioMérieux, Durham, NC), can reliably identify E. rhusiopathiae. MALDI-TOF mass
spectrometry can also identify E. rhusiopathiae. FDA-cleared databases for both Bruker
biotyper CA and Vitek MS systems do not include Erysipelothrix species. However, the
Bruker biotyper RUO database includes mass spectral proﬁles (MSP) for both E. rhusio-
pathiae and E. tonsillarum, while the Vitek MS KnowledgeBase RUO library only includes
E. rhusiopathiae. While 16S rRNA sequencing has been used to identify Erysipelothrix
species, the99% sequence identity of the 16S rRNA gene between some Erysipelothrix
species may preclude use of this method for species-level identiﬁcation (2).
Erysipelothrix spp. are intrinsically resistant to vancomycin; thus, prompt and accu-
rate identiﬁcation is critical to ensure effective antibiotic therapy. Ampicillin and
penicillin are the treatment of choice for both localized and systemic Erysipelothrix
infections, as resistance to these agents has not been described. Other beta-lactams,
including extended-spectrum cephalosporins and carbapenems, have comparable in
vitro activity against Erysipelothrix isolates. In penicillin-allergic patients, erythromycin,
clindamycin, and ﬂuoroquinolones can be considered. Although susceptibility testing is
usually unnecessary, testing may be warranted for penicillin-allergic patients, as resis-
tance to clindamycin and erythromycin has been noted. Antimicrobial susceptibility
testing guidelines and interpretive breakpoints for Erysipelothrix rhusiopathiae are
published in the M45 document from Clinical and Laboratory Standards Institute (CLSI)
(6). Treatment with aminoglycosides and sulfonamides is not recommended, as Erysip-
elothrix isolates are frequently resistant to these agents.
In summary, we present a case of Erysipelothrix rhusiopathiae bloodstream infection
and endocarditis in a patient on chronic steroids due to rheumatoid arthritis. This
isolate was identiﬁed using MALDI-TOF MS and conﬁrmed with biochemical testing.
Rapid and accurate identiﬁcation of this isolate facilitated prompt initiation of appro-
priate antimicrobial therapy, which contributed to successful treatment and recovery of
the patient.
SELF-ASSESSMENT QUESTIONS
1. Which of the following exposures is associated with the highest risk of Erysip-
elothrix rhusiopathiae exposure and subsequent infection?
a. Sustaining a cut while working in an abattoir
b. Consuming unpasteurized dairy products
c. Hunting game in a wooded area
d. Harvesting crops on a farm
2. Erysipelothrix spp. exhibit which of the following phenotypes on biochemical
tests, differentiating them from other aerobic, non-spore-forming Gram-positive
bacilli?
TABLE 1 Biochemical characteristics differentiating Erysipelothrix rhusiopathiae from select non-spore-forming Gram-positive bacillia
Characteristic Erysipelothrix spp. Lactobacillus spp. Listeria spp. Corynebacterium spp.
Gram stain Short bacilli, rounded ends;
occurs singly, short chains
or long ﬁlaments








Width (m) 0.2–0.5 0.5–1 0.4–0.5 0.3–0.6
Length (m) 0.8–2.5 2–10 0.5–2 1.5–8
Hemolysis  /None  None
Catalase    
Esculin hydrolysis    b
H2S on TSI    
Motility    
Notable intrinsic resistance Vancomycin Vancomycinc Cephalosporins None
a, positive; , negative.
bRare Corynebacterium species are positive for esculin hydrolysis.
cSome Lactobacillus species are intrinsically vancomycin resistant, including Lactobacillus rhamnosus and Lactobacillus casei/L. paracasei, among others.
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a. Catalase (), beta-hemolytic, H2S on triple sugar iron (TSI) Agar ()
b. Catalase (), motility (), H2S on TSI Agar ()
c. Catalase (), alpha-hemolytic, H2S on TSI Agar ()
d. Catalase (), motility (), H2S on TSI Agar ()
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